IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 879 
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2871    
    Printed155    
    Emailed2    
    PDF Downloaded159    
    Comments [Add]    
    Cited by others 1    

Recommend this journal

 

 SHORT COMMUNICATION
Year : 2011  |  Volume : 43  |  Issue : 2  |  Page : 207-209

Safety of single-dose nevirapine for prevention of vertical transmission of human immunodeficiency virus infection


1 Department of Pharmacology, Government Medical College, Miraj, India
2 Department of Obstetrics and Gynecology, Government Medical College, Miraj, India

Correspondence Address:
Mangala Bhaskar Murthy
Department of Pharmacology, Government Medical College, Miraj
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0253-7613.77372

Rights and Permissions

Introduction : Nevirapine administered as a single dose each to the mother and child within 72 h after birth is used to prevent vertical transmission of human immunodeficiency virus (HIV) under the prevention of parent to child transmission of HIV program (PPTCT). The efficacy of nevirapine in this regard has been proved beyond doubt, but there are unresolved questions about its safety. Hence, the primary objective of this study was to evaluate the safety of this regime. Materials and Methods : HIV-positive pregnant women who consented to participate in the study received a single oral dose of 200 mg nevirapine at the onset of labor followed by administration of 2 mg/kg of nevirapine syrup to the newborn within 72 h of birth. Both mother and child were followed up for 1 week postpartum to note the occurrence of any adverse reactions. Results : The mother and child followed up for 1 week postpartum did not show any serious adverse reactions in the present study. Mothers reported adverse reactions like nausea, vomiting, and headache which were self-limiting and did not require any intervention. Conclusion : The present study substantiates the safety of nevirapine.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow